What's in K. C. Rasmussen's pipeline?

K. C. Rasmussen has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with K. C. Rasmussen's portfolio?

Top competitors by shared drug class: University Hospital, Clermont-Ferrand, University of the Philippines.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/k-c-rasmussen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

K. C. Rasmussen — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

K. C. Rasmussen pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Ringer-lactate "SAD"	Ringer-lactate "SAD"	marketed
HES 130/04	HES 130/04	marketed	Synthetic colloid / Plasma volume expander		Critical Care / Anesthesia

Therapeutic area mix

Critical Care / Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

University Hospital, Clermont-Ferrand · 1 shared drug class
University of the Philippines · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for K. C. Rasmussen:

Cite this brief

Drug Landscape (2026). K. C. Rasmussen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/k-c-rasmussen. Accessed 2026-06-10.